22,090 Shares in ResMed Inc. (NYSE:RMD) Purchased by Mawer Investment Management Ltd.

Mawer Investment Management Ltd. acquired a new stake in shares of ResMed Inc. (NYSE:RMD - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 22,090 shares of the medical equipment provider's stock, valued at approximately $3,800,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Principal Securities Inc. acquired a new position in ResMed in the 4th quarter valued at $49,000. Moss Adams Wealth Advisors LLC grew its holdings in ResMed by 13.4% in the fourth quarter. Moss Adams Wealth Advisors LLC now owns 2,730 shares of the medical equipment provider's stock worth $470,000 after purchasing an additional 322 shares during the period. Charles Schwab Investment Management Inc. raised its position in shares of ResMed by 5.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 863,289 shares of the medical equipment provider's stock worth $148,503,000 after purchasing an additional 46,113 shares during the period. Apollon Wealth Management LLC bought a new position in ResMed in the 4th quarter valued at about $206,000. Finally, Lincoln National Corp purchased a new position in ResMed during the 4th quarter worth $618,000. 54.98% of the stock is currently owned by institutional investors.

ResMed Trading Down 1.4 %

NYSE:RMD traded down $3.02 during mid-day trading on Friday, reaching $213.82. The company's stock had a trading volume of 635,286 shares, compared to its average volume of 1,339,499. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.04 and a quick ratio of 1.97. The stock has a market cap of $31.41 billion, a P/E ratio of 32.84, a P/E/G ratio of 2.65 and a beta of 0.64. The company's fifty day simple moving average is $194.32 and its two-hundred day simple moving average is $177.27. ResMed Inc. has a twelve month low of $132.24 and a twelve month high of $237.26.

ResMed (NYSE:RMD - Get Free Report) last released its quarterly earnings results on Thursday, April 25th. The medical equipment provider reported $2.13 earnings per share for the quarter, topping analysts' consensus estimates of $1.91 by $0.22. The business had revenue of $1.20 billion during the quarter, compared to the consensus estimate of $1.17 billion. ResMed had a net margin of 20.91% and a return on equity of 24.43%. The business's quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.68 earnings per share. On average, equities analysts predict that ResMed Inc. will post 7.59 EPS for the current year.

ResMed Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 13th. Shareholders of record on Thursday, May 9th will be given a dividend of $0.48 per share. The ex-dividend date is Wednesday, May 8th. This represents a $1.92 dividend on an annualized basis and a yield of 0.90%. ResMed's payout ratio is presently 29.49%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on RMD shares. UBS Group increased their target price on shares of ResMed from $175.00 to $180.00 and gave the stock a "neutral" rating in a research report on Thursday, January 25th. Mizuho reaffirmed a "buy" rating and set a $215.00 price objective on shares of ResMed in a research report on Wednesday, March 27th. Royal Bank of Canada raised their price target on ResMed from $187.00 to $200.00 and gave the company a "sector perform" rating in a report on Friday, April 26th. KeyCorp lifted their price target on shares of ResMed from $227.00 to $238.00 and gave the stock an "overweight" rating in a research note on Friday, April 26th. Finally, Oppenheimer dropped their price target on shares of ResMed from $205.00 to $200.00 and set an "outperform" rating on the stock in a research note on Friday, April 26th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $202.80.

Insider Transactions at ResMed

In related news, CEO Michael J. Farrell sold 14,683 shares of the firm's stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $216.50, for a total value of $3,178,869.50. Following the transaction, the chief executive officer now directly owns 440,752 shares in the company, valued at approximately $95,422,808. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In related news, Director Peter C. Farrell sold 10,935 shares of ResMed stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $182.66, for a total transaction of $1,997,387.10. Following the transaction, the director now owns 157,404 shares of the company's stock, valued at approximately $28,751,414.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael J. Farrell sold 14,683 shares of the firm's stock in a transaction that occurred on Tuesday, May 7th. The stock was sold at an average price of $216.50, for a total transaction of $3,178,869.50. Following the sale, the chief executive officer now owns 440,752 shares in the company, valued at $95,422,808. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 26,324 shares of company stock valued at $5,316,828. 1.21% of the stock is owned by insiders.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. It operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes.